Dacarbazino [Inn-Spanish]

Dacarbazino [Inn-Spanish] Brand names, Dacarbazino [Inn-Spanish] Analogs

Dacarbazino [Inn-Spanish] Brand Names Mixture

No information avaliable

Dacarbazino [Inn-Spanish] Chemical_Formula

C₆H₁₀N₆O

Dacarbazino [Inn-Spanish] RX_link

http://www.rxlist.com/cgi/generic2/dacarbazine.htm

Dacarbazino [Inn-Spanish] fda sheet

http://www.accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN=dacarbazine

Dacarbazino [Inn-Spanish] msds (material safety sheet)

Dacarbazino [Inn-Spanish] Synthesis Reference

Zambito et al.; Nucleic Acid Chem.; 1978; 3,8,9,10(1978);.

Dacarbazino [Inn-Spanish] Molecular Weight

182.183 g/mol

Dacarbazino [Inn-Spanish] Melting Point

205 ^oC

Dacarbazino [Inn-Spanish] H₂O Solubility

4220 mg/L

Dacarbazino [Inn-Spanish] State

Solid

Dacarbazino [Inn-Spanish] LogP

-1.938

Dacarbazino [Inn-Spanish] Dosage Forms

Liquid; Powder for solution

Dacarbazino [Inn-Spanish] Indication

For the treatment of metastatic malignant melanoma. In addition, DTIC-Dome is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other effective agents

Dacarbazino [Inn-Spanish] Pharmacology

After intravenous administration of DTIC-Dome, the volume of distribution exceeds total body water content suggesting localization in some body tissue, probably the liver. Its disappearance from the plasma is biphasic with initial half-life of 19 minutes and a terminal half-life of 5 hours. 1 In a patient with renal and hepatic dysfunctions, the half-lives were lengthened to 55 minutes and 7.2 hours. 1 The average cumulative excretion of unchanged DTIC in the urine is 40% of the injected dose in 6 hours. 1 DTIC is subject to renal tubular secretion rather than glomerular filtration. At therapeutic concentrations DTIC is not appreciably bound to human plasma protein.

Dacarbazino [Inn-Spanish] Absorption

Erratic, slow and incomplete

Dacarbazino [Inn-Spanish] side effects and Toxicity

LD₅₀=350mg/kg (orally in mice)

Dacarbazino [Inn-Spanish] Patient Information

This medicine is a type of chemotherapy for treating cancers of the
blood and certain other cancers. This medicine interfers with the way
cancer cells grow, Take your doses on a regular scheduled time and DO
NOT take this medicine more often than directed by your health care
provider. Finish the full course prescribed by your health care provider.
DO NOT stop taking this medicine unless diredted to do so by your health
care provider. While taking this medicine, you make get infection more
easily. Call your doctor if you get a fever, chills, or sore throat.
Drink plenty of water with this medicine.

Dacarbazino [Inn-Spanish] Organisms Affected

Humans and other mammals